Evaxion Biotech, CCIT, SSI and DTU enter into collaboration on the development of patient-tailored vaccines to attack cancer cells.

Evaxion is joining a four-year research collaboration to develop a therapeutic cancer vaccine designed so that the immune system recognizes unique changes in the individual patient’s cells. Through gene sequencing and artificial intelligence, the new and promising immunotherapy will be tailored to the individual patient. This should result in the effective elimination of cancer cells without the side effects seen in existing therapies.

Read more (English)

Recent News